Raltegravir: is a 400 mg once-daily dose enough?

被引：6

作者：

Lanzafame, Massimiliano ^{[1
]}

Hill, Andrew ^{[2
]}

Lattuada, Emanuela ^{[1
]}

Calcagno, Andrea ^{[3
]}

Bonora, Stefano ^{[3
]}

机构：

[1] GB Rossi Hosp, Unit Diag & Therapy HIV Infect, I-37134 Verona, Italy

[2] Univ Liverpool, Pharmacol Res Labs, Liverpool L69 3GF, Merseyside, England

[3] Amedeo di Savoia Hosp, Dept Infect Dis, I-101159 Turin, Italy

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2010年 / 65卷 / 03期

关键词：

atazanavir; HAART; HIV infection; pharmacokinetics; INTEGRASE INHIBITOR RALTEGRAVIR; RANDOMIZED CONTROLLED-TRIAL; TREATMENT-NAIVE PATIENTS; HIV-1; INTEGRASE; COMBINATION THERAPY; SAFETY; PHARMACOKINETICS; TOLERABILITY; INFECTION; EFFICACY;

D O I：

10.1093/jac/dkp488

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

引用

页码：595 / 597

页数：3

共 6 条

[1] Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial [J].

Grinsztejn, Beatriz ;

Nguyen, Bach-Yen ;

Katlama, Christine ;

Gatell, Jose M. ;

Lazzarin, Adriano ;

Vittecoq, Daniel ;

Gonzalez, Charles J. ;

Chen, Joshua ;

Harvey, Charlotte M. ;

Isaacs, Robin D. .

LANCET, 2007, 369 (9569) :1261-1269

[2] Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects [J].

Iwamoto, M. ;

Wenning, L. A. ;

Petry, A. S. ;

Laethem, M. ;

De Smet, M. ;

Kost, J. T. ;

Merschman, S. A. ;

Strohmaier, K. M. ;

Ramael, S. ;

Lasseter, K. C. ;

Stone, J. A. ;

Gottesdiener, K. M. ;

Wagner, J. A. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (02) :293-299

[3] Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial [J].

Lennox, Jeffrey L. ;

Dejesus, Edwin ;

Lazzarin, Adriano ;

Pollard, Richard B. ;

Ramalho Madruga, Jose Valdez ;

Berger, Daniel S. ;

Zhao, Jing ;

Xu, Xio ;

Williams-Diaz, Angela ;

Rodgers, Anthony J. ;

Barnard, Richard J. O. ;

Miller, Michael D. ;

DiNubile, Mark J. ;

Nguyen, Bach-Yen ;

Leavitt, Randi ;

Sklar, Peter .

LANCET, 2009, 374 (9692) :796-806

[4] Rapid and durable Antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection - Results of a 48-week controlled study [J].

Markowitz, Martin ;

Nguyen, Bach-Yen ;

Gotuzzo, Eduardo ;

Mendo, Fernando ;

Ratanasuwan, Winai ;

Kovacs, Colin ;

Prada, Guillermo ;

Morales-Ramirez, Javier O. ;

Crumpacker, Clyde S. ;

Isaacs, Robin D. ;

Gilde, Lucinda R. ;

Wan, Hong ;

Miller, Michael D. ;

Wenning, Larissa A. ;

Teppler, Hedy .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 46 (02) :125-133

[5] Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals [J].

Markowitz, Martin ;

Morales-Ramirez, Javier O. ;

Nguyen, Bach-Yen ;

Kovacs, Colin M. ;

Steigbigel, Roy T. ;

Cooper, David A. ;

Liporace, Ralph ;

Schwartz, Robert ;

Isaacs, Robin ;

Gilde, Lucinda R. ;

Penning, Larissa ;

Zhao, Jing ;

Teppler, Hedy .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 43 (05) :509-515

[6]

NEELY M, 2009, 5 IAS C HIV PATH CAP

← 1 →